A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Clinical trial NCT04272203 · TERMINATED

Trial details

NCT number: NCT04272203
Sponsor: AbbVie
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Non Small Cell Lung Cancer Cancer

Start date: 2020-05-05
Primary completion: 2022-06-27
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.